Moderna Teases M&A Interest As Pandemic Expected To Wind Down
Biotech Anticipates Four Phase III Programs In Clinic in Q2
Spikevax revenues beat expectations but analysts are bracing for the eventuality of lower vaccine revenues as COVID-19 becomes endemic. Moderna will have four new vaccines in Phase III this quarter.
